Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.60 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | ALB | P02768 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13526930 | 0.93 | SIRT5 (0.54) | SIRT5FOLH1ALBKDM4EMAPK1 | |
| SCHEMBL12922150 | 0.93 | SIRT5 (0.54) | SIRT5FOLH1ALBKDM4EMAPK1 | |
| SCHEMBL16285431 | 0.88 | SIRT5 (0.53) | SIRT5FOLH1ALBKDM4EMAPK1 | |
| SCHEMBL20341058 | 0.87 | SIRT5 (0.63) | SIRT5FOLH1ALBKDM4EMAPK1 | |
| SCHEMBL12311708 | 0.87 | SIRT5 (0.65) | SIRT5FOLH1ALBKDM4EMAPK1 | |
| SCHEMBL13635157 | 0.87 | SIRT5 (0.65) | SIRT5FOLH1ALBKDM4EMAPK1 | |
| SCHEMBL10027319 | 0.86 | MEN1 (0.52) | SIRT5ALBTLR2SIRT6SIRT1 | |
| SCHEMBL25457917 | 0.85 | SIRT5 (0.51) | SIRT5FOLH1ALBKDM4EMAPK1 | |
| SCHEMBL13120897 | 0.85 | SIRT5 (0.51) | SIRT5FOLH1ALBKDM4EMAPK1 | |
| SCHEMBL18461328 | 0.85 | ALB (0.65) | SIRT5FOLH1ALBKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009205-A1 | Modified Fc Molecules | AMGEN INC. | 2012-01-12 | — | — | US | disclosed |
| US-7833979-B2 | conjugated polymer drug contains toxin protein and polyethylene glycol; treating autoimmune diseases, such as multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, dermatitis, rheumatoid arthritis, psoriasis; asthma, allergy, restinosis, fibrosis, scleroderma, glomerulonephritis | AMGEN INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7488590-B2 | Fusion of Fc domains with biologically active peptides; selecting peptide that modulates the activity of AGP-3, preparing a gene construct; expressing the pharmacologically active compound in which an Fc domain is covalently linked to peptide | AMGEN INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20090022744-A1 | Modified Fc molecules | AMGEN INC. | 2009-01-22 | — | — | US | disclosed |
| US-7442778-B2 | Modified Fc molecules | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080254020-A1 | Therapeutic Peptides | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070269369-A1 | Modified Fc molecules | AMGEN INC. | 2007-11-22 | — | — | US | disclosed |
| US-7259137-B2 | Tumor necrosis factors; cytokines; immunoglobulins; autoimmune diseases | AMGEN INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20070071764-A1 | conjugated polymer drug contains toxin protein and polyethylene glycol; treating autoimmune diseases, such as multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, dermatitis, rheumatoid arthritis, psoriasis; asthma, allergy, restinosis, fibrosis, scleroderma, glomerulonephritis | AMGEN INC. | 2007-03-29 | — | — | US | disclosed |
| US-7186810-B2 | Modified peptides as therapeutic agents | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7169905-B2 | Modified peptides as therapeutic agents | AMGEN INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070071764-A1 | conjugated polymer drug contains toxin protein and polyethylene glycol; treating autoimmune diseases, such as multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, dermatitis, rheumatoid arthritis, psoriasis; asthma, allergy, restinosis, fibrosis, scleroderma, glomerulonephritis | F11, F13A1, F12 | SIRT5 4848/4885FOLH1 1479/4885ALB 1918/4885 |
| US-20090022744-A1 | Modified Fc molecules | FCGR3B, FCGR2A, FCGR1A | SIRT5 3063/4885FOLH1 538/4885ALB 456/4885 |
| US-20080254020-A1 | Therapeutic Peptides | FCGRT, FCGR3B, FCGR1A | SIRT5 3305/4885FOLH1 162/4885ALB 403/4885 |
| US-20070269369-A1 | Modified Fc molecules | FCGR1A, FCGRT, FCGR2A | SIRT5 4384/4885FOLH1 126/4885ALB 645/4885 |
| US-20120009205-A1 | Modified Fc Molecules | FCGR1A, FCGRT, FCGR2A | SIRT5 4384/4885FOLH1 126/4885ALB 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.